Goldenwell Biotech (GWLL) Free Cash Flow (2019 - 2025)
Goldenwell Biotech filings provide 7 years of Free Cash Flow readings, the most recent being -$30885.0 for Q3 2025.
- On a quarterly basis, Free Cash Flow fell 47.32% to -$30885.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$29133.0, a 75.06% increase, with the full-year FY2024 number at -$123077.0, down 8.77% from a year prior.
- Free Cash Flow hit -$30885.0 in Q3 2025 for Goldenwell Biotech, down from $59380.0 in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $59380.0 in Q2 2025 to a low of -$917090.0 in Q4 2022.
- Median Free Cash Flow over the past 5 years was -$29010.0 (2024), compared with a mean of -$86571.2.
- Biggest five-year swings in Free Cash Flow: crashed 105675.35% in 2021 and later soared 224.35% in 2025.
- Goldenwell Biotech's Free Cash Flow stood at -$19373.0 in 2021, then plummeted by 4633.86% to -$917090.0 in 2022, then soared by 97.92% to -$19076.0 in 2023, then plummeted by 32.89% to -$25351.0 in 2024, then decreased by 21.83% to -$30885.0 in 2025.
- The last three reported values for Free Cash Flow were -$30885.0 (Q3 2025), $59380.0 (Q2 2025), and -$32277.0 (Q1 2025) per Business Quant data.